Accéder au contenu
MilliporeSigma
Toutes les photos(1)

Documents

L6668

Sigma-Aldrich

Lercanidipine hydrochloride

≥98% (HPLC), powder, dihydropyridine calcium-channel blocker

Synonyme(s) :

1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester 3,5-pyridinedicarboxylic acid hydrochloride

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C36H41N3O6 · HCl
Numéro CAS:
132866-11-6
Poids moléculaire :
648.19
Numéro MDL:
MFCD07773089
Code UNSPSC :
12352200
ID de substance PubChem :
24724527
Nomenclature NACRES :
NA.77

product name

Lercanidipine hydrochloride, ≥98% (HPLC)

Pureté

≥98% (HPLC)

Forme

powder

Conditions de stockage

desiccated
protect from light

Couleur

yellow

Auteur

Forest Labs

Température de stockage

2-8°C

Chaîne SMILES 

O=C(OC)C1=C(C)NC(C)=C(C(OC(C)(C)CN(C)CCC(C2=CC=CC=C2)C3=CC=CC=C3)=O)C1C4=CC([N+]([O-])=O)=CC=C4.Cl

InChI

1S/C36H41N3O6.ClH/c1-24-31(34(40)44-6)33(28-18-13-19-29(22-28)39(42)43)32(25(2)37-24)35(41)45-36(3,4)23-38(5)21-20-30(26-14-9-7-10-15-26)27-16-11-8-12-17-27;/h7-19,22,30,33,37H,20-21,23H2,1-6H3;1H

Clé InChI

WMFYOYKPJLRMJI-UHFFFAOYSA-N

Actions biochimiques/physiologiques

Lercanidipine hydrochloride is a L-type (Cav1.2b) vascular channel antagonist; L-type (Cav1.2a) cardiac channel agonist voltage-dependent and highly lipophylic compound, which exhibits a slower onset and longer duration of action than other calcium channel antagonists; an antihypertensive agent in patients with mild-to-moderate hypertension; more vasoselective than lacidipine and amlodipine.

Caractéristiques et avantages

This compound was developed by Forest Labs. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictogrammes

Skull and crossbones
GHS06

Mention d'avertissement

Danger

Mentions de danger

H301

Classification des risques

Acute Tox. 3 Oral

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 1

1 of 1

Ketoprofen ≥98% (TLC)

Sigma-Aldrich

K1751

Ketoprofen

Jürgen Scholze et al.
Expert opinion on pharmacotherapy, 12(18), 2771-2779 (2011-10-18)
A fixed-dose combination (FDC) of enalapril and lercanidipine has been shown to be effective and safe in reducing blood pressure in randomized clinical trials. This study aims to determine effectiveness and safety in daily practice. This was a prospective, open-label
Yuezhang Chen et al.
Molecular medicine reports, 16(4), 4545-4552 (2017-08-30)
Previous studies have demonstrated that lercanidipine, a calcium channel blocker, may protect against cardiac hypertrophy; however, the underlying mechanisms remain unclear. In the present study, the effects of lercanidipine on hypertrophy and the mechanisms involved were investigated. Cardiomyocytes isolated from
P-J Hsiao et al.
Clinical nephrology, 74(3), 217-222 (2010-09-24)
Lercanidipine, a novel dihydropyridine calcium channel antagonist, has been reported to cause sterile cloudy effluent in patients on continuous ambulatory peritoneal dialysis (CAPD). The purpose of the study was to evaluate the incidence and clinical course of cloudy effluent associated
Mehmet Gumustas et al.
Talanta, 82(4), 1528-1537 (2010-08-31)
In this study, pK(a) values were determined using the dependence of the retention factor on the pH of the mobile phase for three ionizable substances, namely, enalapril, lercanidipine and ramipril (IS). The effect of the mobile phase composition on the
Huifeng Xu et al.
Gene, 500(2), 207-210 (2012-04-17)
To determine whether the antihypertensive and vascular protective effects of short-term treatment with lercanidipine, a calcium channel blocker, are modulated by the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism. In a self-controlled study, a total of 143 essential hypertensive patients, all permanent
Afficher tous les articles scientifiques apparentés

Articles

Calcium Channels

We offers many products related to calcium channels for your research needs.

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique